by Nick Dragojlovic | May 26, 2014
> In a recent post on Signals, David Kent made the case for government-funded clinical trials of autologous stem cell therapies, since the lack of proven commercialization models in this area make it difficult to attract private investment. Another way of financing...
by Mark Curtis | May 22, 2014
. Welcome to your Update from the Clinic for the month of April. Athersys provides disappointing interim results for its MultiStem® cell therapy in ulcerative colitis patients. Sernova continues to demonstrate safety and biocompatability of its Cell Pouch technology...
by Lisa Willemse | May 21, 2014
> I’m not an academic, but I’ve been to many scientific conferences and read many more papers over the past 10 years or so. I know how important data is in research. I also know how important it is in communications (where visits, likes or shares are...
by David Kent | May 6, 2014
> My last post introduced the large-scale publicly funded clinical trial called BAMI (the effect of intracoronary reinfusion of Bone marrow-derived mononuclear cells on all course mortality in Acute Myocardial Infarction). That post focused on the role of the...
by Mark Curtis | Apr 30, 2014
. Of all the formidable challenges that a biotechnology company will stumble upon in its quest to commercialize, perhaps there is none more frustrating than a failure to get a product reimbursed by payers. After years of navigating the gauntlet of risk that is...
by Paul Krzyzanowski | Apr 22, 2014
> If you’ve stayed current with the STAP cell fiasco you know it’s been a wild ride. STAP cells, or Stimulus-Triggered Acquisition of Pluripotency cells, caught the imagination of many in late January through their sheer simplicity: You hit cells with a shock of...
Comments